93 related articles for article (PubMed ID: 21615354)
1. Galantamine and behavior in Alzheimer disease: analysis of four trials.
Kavanagh S; Gaudig M; Van Baelen B; Adami M; Delgado A; Guzman C; Jedenius E; Schäuble B
Acta Neurol Scand; 2011 Nov; 124(5):302-8. PubMed ID: 21615354
[TBL] [Abstract][Full Text] [Related]
2. Effects of galantamine on behavioural and psychological disturbances and caregiver burden in patients with Alzheimer's disease.
Monsch AU; Giannakopoulos P;
Curr Med Res Opin; 2004 Jun; 20(6):931-8. PubMed ID: 15200752
[TBL] [Abstract][Full Text] [Related]
3. Galantamine prolonged-release formulation in the treatment of mild to moderate Alzheimer's disease.
Brodaty H; Corey-Bloom J; Potocnik FC; Truyen L; Gold M; Damaraju CR
Dement Geriatr Cogn Disord; 2005; 20(2-3):120-32. PubMed ID: 15990426
[TBL] [Abstract][Full Text] [Related]
4. Galantamine provides broad benefits in patients with 'advanced moderate' Alzheimer's disease (MMSE < or = 12) for up to six months.
Wilkinson DG; Hock C; Farlow M; van Baelen B; Schwalen S
Int J Clin Pract; 2002 Sep; 56(7):509-14. PubMed ID: 12296613
[TBL] [Abstract][Full Text] [Related]
5. The effects of galantamine treatment on caregiver time in Alzheimer's disease.
Sano M; Wilcock GK; van Baelen B; Kavanagh S
Int J Geriatr Psychiatry; 2003 Oct; 18(10):942-50. PubMed ID: 14533127
[TBL] [Abstract][Full Text] [Related]
6. Omega-3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms.
Freund-Levi Y; Basun H; Cederholm T; Faxén-Irving G; Garlind A; Grut M; Vedin I; Palmblad J; Wahlund LO; Eriksdotter-Jönhagen M
Int J Geriatr Psychiatry; 2008 Feb; 23(2):161-9. PubMed ID: 17582225
[TBL] [Abstract][Full Text] [Related]
7. Reduction of behavioral disturbances and caregiver distress by galantamine in patients with Alzheimer's disease.
Cummings JL; Schneider L; Tariot PN; Kershaw PR; Yuan W
Am J Psychiatry; 2004 Mar; 161(3):532-8. PubMed ID: 14992980
[TBL] [Abstract][Full Text] [Related]
8. Cessation versus continuation of galantamine treatment after 12 months of therapy in patients with Alzheimer's disease: a randomized, double blind, placebo controlled withdrawal trial.
Scarpini E; Bruno G; Zappalà G; Adami M; Richarz U; Gaudig M; Jacobs A; Schäuble B
J Alzheimers Dis; 2011; 26(2):211-20. PubMed ID: 21606568
[TBL] [Abstract][Full Text] [Related]
9. Galantamine treatment in Alzheimer's disease with cerebrovascular disease: responder analyses from a randomized, controlled trial (GAL-INT-6).
Erkinjuntti T; Gauthier S; Bullock R; Kurz A; Hammond G; Schwalen S; Zhu Y; Brashear R
J Psychopharmacol; 2008 Sep; 22(7):761-8. PubMed ID: 18308781
[TBL] [Abstract][Full Text] [Related]
10. Effect of galantamine on verbal repetition in AD: a secondary analysis of the VISTA trial.
Rockwood K; Fay S; Jarrett P; Asp E
Neurology; 2007 Apr; 68(14):1116-21. PubMed ID: 17404193
[TBL] [Abstract][Full Text] [Related]
11. Improvement in behavioural symptoms in patients with moderate to severe Alzheimer's disease by memantine: a pooled data analysis.
Gauthier S; Loft H; Cummings J
Int J Geriatr Psychiatry; 2008 May; 23(5):537-45. PubMed ID: 18058838
[TBL] [Abstract][Full Text] [Related]
12. Effects of galantamine in patients with mild Alzheimer's disease.
Orgogozo JM; Small GW; Hammond G; Van Baelen B; Schwalen S
Curr Med Res Opin; 2004 Nov; 20(11):1815-20. PubMed ID: 15537482
[TBL] [Abstract][Full Text] [Related]
13. Galantamine treatment of problematic behavior in Alzheimer disease: post-hoc analysis of pooled data from three large trials.
Herrmann N; Rabheru K; Wang J; Binder C
Am J Geriatr Psychiatry; 2005 Jun; 13(6):527-34. PubMed ID: 15956273
[TBL] [Abstract][Full Text] [Related]
14. A 2-year open-label study of galantamine therapy in Chinese Alzheimer's disease patients in Hong Kong.
Chu LW; Yik PY; Mok W; Chung CP
Int J Clin Pract; 2007 Mar; 61(3):403-10. PubMed ID: 17313606
[TBL] [Abstract][Full Text] [Related]
15. Treatment strategies for the behavioral symptoms of Alzheimer's disease: focus on early pharmacologic intervention.
Beier MT
Pharmacotherapy; 2007 Mar; 27(3):399-411. PubMed ID: 17316151
[TBL] [Abstract][Full Text] [Related]
16. Analyses of mortality risk in patients with dementia treated with galantamine.
Feldman HH; Pirttila T; Dartigues JF; Everitt B; Van Baelen B; Brashear HR; Berlin JA; Battisti WP; Kavanagh S
Acta Neurol Scand; 2009 Jan; 119(1):22-31. PubMed ID: 18518863
[TBL] [Abstract][Full Text] [Related]
17. Long-term effects of galantamine on cognitive function in Alzheimer's disease: a large-scale international retrospective study.
Kavanagh S; Van Baelen B; Schäuble B
J Alzheimers Dis; 2011; 27(3):521-30. PubMed ID: 21891871
[TBL] [Abstract][Full Text] [Related]
18. Neuropsychiatric symptoms in mild dementia with lewy bodies and Alzheimer's disease.
Bjoerke-Bertheussen J; Ehrt U; Rongve A; Ballard C; Aarsland D
Dement Geriatr Cogn Disord; 2012; 34(1):1-6. PubMed ID: 22854420
[TBL] [Abstract][Full Text] [Related]
19. Effects of memantine on behavioural symptoms in Alzheimer's disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies.
Gauthier S; Wirth Y; Möbius HJ
Int J Geriatr Psychiatry; 2005 May; 20(5):459-64. PubMed ID: 15852444
[TBL] [Abstract][Full Text] [Related]
20. Early onset effects of galantamine treatment on attention in patients with Alzheimer's disease.
Vellas B; Cunha L; Gertz HJ; De Deyn PP; Wesnes K; Hammond G; Schwalen S;
Curr Med Res Opin; 2005 Sep; 21(9):1423-9. PubMed ID: 16197661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
